Naveris Announces Expansion of the NavDx® Test in Anal Cancer Molecular Residual Disease Surveillance

The NavDx test demonstrates high performance in detecting recurrent disease, providing an enhanced and widely accessible surveillance tool for HPV+ anal squamous cell carcinoma patients

Excerpt from the Press Release:

WALTHAM, Mass.–(BUSINESS WIRE)–Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the expanded commercial availability of the NavDx test for Molecular Residual Disease (MRD) detection in anal squamous cell carcinoma (ASCC) patients. NavDx, Naveris’ proprietary flagship blood test, is the first and only clinically validated circulating tumor TTMV^®-HPV DNA blood test that provides a non-invasive and precise method that can detect MRD before there is clinical or radiographic evidence of cancer recurrence.

The commercial expansion coincides with the publication of clinical validity and utility data in the journal Cancers¹that demonstrates the NavDx test’s ability to accurately and reliably detect MRD in HPV-positive anal cancer patients in a multi-center, real-world cohort.

Dr. Barry M. Berger, Chief Medical Officer of Naveris, commented: “With an impressive per-test positive predictive value (PPV) of 98% and a negative predictive value (NPV) of 95%, the NavDx test demonstrates exceptional clinical value in detecting and ruling out disease recurrence in ASCC patients. This offers real utility for physicians, allowing them to accurately assess whether a patient has residual disease and implementing the most appropriate course of care without unnecessary delays. This expanded use of NavDx represents a critical step forward in advancing both precision medicine and the overall management of HPV-related anal cancer.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release